Phaseline

Companies › Galecto Biotech

Galecto Biotech: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
GB2064
LOXL2 inhibitor
LOXL2Phase 2Myelofibrosis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04679870GB2064Phase 2MyelofibrosisOncologyDec 2023

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

LOXL2 (1)

Companies with the same targets

Bristol-Myers Squibb

Companies built like this

NanoEcho Syncromune VSPharmTech BPGbio Shanghai AB PharmaTech

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.